Production of oligodendrocytes from placenta-derived stem cells

• US 8,071,376 B2
• Filed: 10/13/2006
• Issued: 12/06/2011
• Est. Priority Date: 10/13/2005
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Heidaran, Mohammad
• Primary Examiner(s): WEHBE, ANNE MARIE SABRINA
• Application Number:
  US11/580,625
• Publication Number:
  US 20070134210A1
• Time in Patent Office: 1,880 Days
• Field of Search: 435/377, 435/325
• US Class Current: 435/377
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Abstract

The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.

Claims

1. A method of producing an oligodendrocyte, comprising culturing a placental stem cell under conditions and for a time sufficient for said stem cell to exhibit a characteristic of an oligodendrocyte, wherein said placental stem cell is not a trophoblast, wherein said culturing comprises contacting said stem cell with a phosphodiesterase inhibitor;

and wherein said characteristic is the production of myelin oligodendrocyte specific protein (MOSP) or expression of a gene encoding MOSP.

2. The method of claim 1, wherein said culturing comprises contacting said stem cell with isobutylmethylxanthine (IBMX).

3. The method of claim 1, wherein said placental stem cell expresses one or more of the markers CD73, CD105, CD200, HLA-G, or OCT-4;

and does not express one or more of CD34, CD38, or CD45.

4. The method of claim 1, wherein said placental stem cell is:

CD200⁺ and HLA-G⁺;

CD73⁺, CD105⁺, and CD200⁺;

CD200⁺ and OCT-4⁺;

or

CD73⁺, CD105⁺ and HLA-G⁺.

5. The method of claim 3, wherein said placental stem cell is CD10⁺, CD34⁻

, CD105⁺ and CD200⁺.

6. The method of claim 1, wherein said culturing comprises additionally contacting said placental stem cell with one or more of epidermal growth factor (EGF), fibroblast growth factor (FGF), or platelet-derived growth factor (PDGF).

7. The method of claim 1, wherein said culturing comprises additionally contacting said placental stem cell with epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF).

8. The method of claim 1, wherein said placental stem cells are CD10⁺, CD29⁺, CD54⁺, CD90⁺, SH2⁺, SH3⁺, CD34⁻

and CD45⁻

.